DCG-IV is a research drug which acts as a group-selective agonist for the group II metabotropic glutamate receptors (
mGluR2/3).[1] It has potent
neuroprotective and
anticonvulsant effects in animal studies,[2][3][4][5] as well as showing anti-
Parkinsonian effects,[6][7] but also impairs the formation of memories.[8][9]
^Bruno V, Copani A, Battaglia G, Raffaele R, Shinozaki H, Nicoletti F (April 1994). "Protective effect of the metabotropic glutamate receptor agonist, DCG-IV, against excitotoxic neuronal death". European Journal of Pharmacology. 256 (1): 109–12.
doi:
10.1016/0014-2999(94)90624-6.
PMID7517889.
^Yoshioka H, Sugita M, Kinouchi H (September 2009). "Neuroprotective effects of group II metabotropic glutamate receptor agonist DCG-IV on hippocampal neurons in transient forebrain ischemia". Neuroscience Letters. 461 (3): 266–70.
doi:
10.1016/j.neulet.2009.06.056.
PMID19549561.
S2CID23564621.
^Attwell PJ, Singh Kent N, Jane DE, Croucher MJ, Bradford HF (September 1998). "Anticonvulsant and glutamate release-inhibiting properties of the highly potent metabotropic glutamate receptor agonist (2S,2'R, 3'R)-2-(2',3'-dicarboxycyclopropyl)glycine (DCG-IV)". Brain Research. 805 (1–2): 138–43.
doi:
10.1016/S0006-8993(98)00698-2.
PMID9733953.
S2CID10771399.
^Fei Z, Zhang X, Bai HM, Jiang XF, Wang XL (December 2006). "Metabotropic glutamate receptor antagonists and agonists: potential neuroprotectors in diffuse brain injury". Journal of Clinical Neuroscience. 13 (10): 1023–7.
doi:
10.1016/j.jocn.2005.11.042.
PMID17113985.
S2CID6959171.
^Huang LQ, Rowan MJ, Anwyl R (February 1997). "mGluR II agonist inhibition of LTP induction, and mGluR II antagonist inhibition of LTD. induction, in the dentate gyrus in vitro". NeuroReport. 8 (3): 687–93.
doi:
10.1097/00001756-199702100-00022.
PMID9106748.
S2CID42513317.
^Sato T, Tanaka K, Ohnishi Y, Teramoto T, Irifune M, Nishikawa T (February 2004). "Inhibitory effects of group II mGluR-related drugs on memory performance in mice". Physiology & Behavior. 80 (5): 747–58.
doi:
10.1016/j.physbeh.2003.12.010.
PMID14984810.
S2CID33433968.
DCG-IV is a research drug which acts as a group-selective agonist for the group II metabotropic glutamate receptors (
mGluR2/3).[1] It has potent
neuroprotective and
anticonvulsant effects in animal studies,[2][3][4][5] as well as showing anti-
Parkinsonian effects,[6][7] but also impairs the formation of memories.[8][9]
^Bruno V, Copani A, Battaglia G, Raffaele R, Shinozaki H, Nicoletti F (April 1994). "Protective effect of the metabotropic glutamate receptor agonist, DCG-IV, against excitotoxic neuronal death". European Journal of Pharmacology. 256 (1): 109–12.
doi:
10.1016/0014-2999(94)90624-6.
PMID7517889.
^Yoshioka H, Sugita M, Kinouchi H (September 2009). "Neuroprotective effects of group II metabotropic glutamate receptor agonist DCG-IV on hippocampal neurons in transient forebrain ischemia". Neuroscience Letters. 461 (3): 266–70.
doi:
10.1016/j.neulet.2009.06.056.
PMID19549561.
S2CID23564621.
^Attwell PJ, Singh Kent N, Jane DE, Croucher MJ, Bradford HF (September 1998). "Anticonvulsant and glutamate release-inhibiting properties of the highly potent metabotropic glutamate receptor agonist (2S,2'R, 3'R)-2-(2',3'-dicarboxycyclopropyl)glycine (DCG-IV)". Brain Research. 805 (1–2): 138–43.
doi:
10.1016/S0006-8993(98)00698-2.
PMID9733953.
S2CID10771399.
^Fei Z, Zhang X, Bai HM, Jiang XF, Wang XL (December 2006). "Metabotropic glutamate receptor antagonists and agonists: potential neuroprotectors in diffuse brain injury". Journal of Clinical Neuroscience. 13 (10): 1023–7.
doi:
10.1016/j.jocn.2005.11.042.
PMID17113985.
S2CID6959171.
^Huang LQ, Rowan MJ, Anwyl R (February 1997). "mGluR II agonist inhibition of LTP induction, and mGluR II antagonist inhibition of LTD. induction, in the dentate gyrus in vitro". NeuroReport. 8 (3): 687–93.
doi:
10.1097/00001756-199702100-00022.
PMID9106748.
S2CID42513317.
^Sato T, Tanaka K, Ohnishi Y, Teramoto T, Irifune M, Nishikawa T (February 2004). "Inhibitory effects of group II mGluR-related drugs on memory performance in mice". Physiology & Behavior. 80 (5): 747–58.
doi:
10.1016/j.physbeh.2003.12.010.
PMID14984810.
S2CID33433968.